Company Profile

Industry Sector: Biological Research Tools and Medical Devices

Company Overview: LasMed LLC has pioneered the development of diode laser-based stimulators for selective activation of pain through Adelta/C small nerve fibers and TRPV positive DRG/HEK cells. The main implementations of this technology are basic research, clinical and preclinical trials of analgesics in development, and diagnosis of diabetic, HIV, herpes, cancer neuropathies and pain.

Target Market(s): Academic laboratories, pharmaceutical companies, contract research organizations, clinical laboratories, neurology and pain management departments.

Management

Leadership:
Mike Nemenov, PhD: President and Chief Scientific Officer
Vivian Lauderdale, MBA, MS, RAC: VP Regulatory Affairs & Quality Assurance
John Ross: Business strategy and IP attorney

Scientific Advisory Board:
David Yeomans, PhD: Professor, Director of Pain Research, Stanford University,
Miroslav “Misha” Backonja, MD: Director of Neuroscience, CRILifetree

Key Value Drivers

Technology*: The LasMed stimulators test functionality of small nerve fibers (A-delta or/and C). The stimulators are compatible with real-time imaging (fMRI, LEP/EEG, MEG) and quantitative sensory tests (QST) for pain research and diagnosis of small nerve fiber neuropathies in humans and animals.

Competitive Advantage: LasMed technology and pain protocols are the only ones in existence that offer selective activation of A-delta or C small fibers, independently of their depth, location and in any body part. Their translational properties can be utilized in both preclinical trials and in the clinic. The technology is protected by US patents.

Plan & Strategy: Obtain strong efficacy and safety data, then identify a strategic partner to complete clinical development and launch product.

*Technology funded by the NIDA & NINDS and being commercialized under the NIH-CAP

Product Pipeline

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio-research stimulator</td>
<td>SBIR Phase IIB to develop and validate a commercializable low cost diode laser stimulator for preclinical research</td>
<td>Production and Marketing</td>
<td></td>
</tr>
<tr>
<td>Medical stimulator</td>
<td>SBIR Phase IIB to develop and validate a commercializable medical selective diode laser stimulator for clinical research</td>
<td>FDA clearance for clinical research</td>
<td>for clinic including billing code</td>
</tr>
</tbody>
</table>